5-FU based chemotherapy with bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor.

Birgit Gruenberger,Patrick Starlinger,Elisabeth Messinger,Lukas Oehlberger,Sabine Weibrecht,Jan Philipp Jonas,Barbara Weitmayr,Thomas Gruenberger

5-FU based chemotherapy with bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor.

2016

Birgit Gruenberger
Patrick Starlinger
Elisabeth Messinger
Lukas Oehlberger
Sabine Weibrecht
Jan Philipp Jonas
Barbara Weitmayr
Thomas Gruenberger

e23208Background: The benefit of systemic chemotherapie (5-FU based) in combination with Bevacizumab (Bev) in patients (pts) with metastatic colorectal cancer (mCRC) is well proven. Nevertheless, a...

Keywords:

Bevacizumab
Primary tumor
Pathology
Cancer research
Colorectal cancer
Chemotherapy
Medicine
Oncology
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations